SHORT REPORT

Pseudomyxoma peritonei: unusual origin from an ovarian mature cystic teratoma

N Pranesh, L P Menasce, M S Wilson, S T O’Dwyer

Pseudomyxoma peritonei (PMP) is classified into pathologically and prognostically distinct categories, such as disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis. There is overwhelming evidence that DPAM arises from a mucinous adenoma of the appendix. The one exception to this is the presentation of a mature ovarian cystic teratoma as PMP where the appendix is normal. This report describes such a case and discusses the presentation, histopathology, and treatment options.

CASE REPORT

A 39 year old woman presented with a three month history of abdominal distension and an episode of abnormal per vaginal bleeding. Clinical examination revealed a mass arising out of the pelvis and ultrasound examination demonstrated a large multicystic complex mass containing fluid and solid components, arising from the left ovary. The tumour marker CA125 was normal at 11 KU/litre. At laparotomy, copious amounts of free mucin and tenacious mucinous deposits were seen on the surface of the omentum and bowel. There was a 10×12 cm left ovarian mass and a small right ovarian cyst. Peritoneal lavage, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and appendicectomy were performed. After an uneventful recovery she was referred to our PMP centre for further management. Nine months after surgery, an abdominal computed tomography scan shows no evidence of PMP and tumour markers such as carcinoembryonic antigen, CA125, and CA19-9 are within normal limits.

HISTOPATHOLOGY

Macroscopic examination revealed a multiloculated, cystic, left ovarian mass measuring 14×12.5×7.5 cm. The cut surfaces revealed multiple cysts with smooth walls containing mucinous material. One of the cysts contained sebum and hairs. The appendix measured 4 cm with no focal lesions identified on the cut surface.

Paraffin wax embedded sections of the left ovary confirmed the presence of a mature cystic teratoma (dermoid cyst) and a mucinous tumour. The teratomatous component consisted of a cyst lined by keratinising squamous epithelium containing skin appendages, such as sebaceous and apocrine glands (fig 1A). The mucinous component was multiloculated with the cysts lined by a single layer of mucin secreting epithelium (fig 1B). There were intestinal changes characterised by the presence of goblet cells and occasional Paneth cells. Sections of the appendix demonstrated mucinous material on the serosal surface. No abnormal epithelial proliferation was seen along the entire length of its lumen. The surfaces of the uterus and omentum also demonstrated mucinous material but without epithelial elements.

On immunoperoxidase staining, the mucinous epithelium in the ovary was cytokeratin 20 (CK20), carcinoembryonic antigen, and BerEP4 positive and CK7 negative.

Figure 1  (A) Teratomatous component; (B) mucinous component.

Abbreviations: CK, cytokeratin; DPAM, disseminated peritoneal adenomucinosis; PMCA, peritoneal mucinous carcinomatosis; PMP, pseudomyxoma peritonei
**DISCUSSION**

Although the association of appendical mucinous tumours/mucocoele with PMP has long been recognised, the true origin of PMP in women who have simultaneous appendical and ovarian tumours has been a dilemma. Advances in immunohistochemical and molecular genetic techniques have provided compelling evidence that the source of PMP is an appendiceal mucinous tumour."The lack of lining epithelium in the peritoneal mucinous deposits, combined with normal tumour markers and normal imaging, make it difficult to outline the treatment that should be offered to our patient".

An appendiceal mucinous neoplasm can be found in almost all cases of DPAM/PMP with the notable exception of those arising in the gastrointestinal component of a mature cystic teratoma. Primary ovarian mucinous tumours are usually CK7 positive and show variable expression of CK20, unlike those associated with mature teratomas, which have the CK20+/CK7− phenotype. The above factors, particularly the lack of lining epithelium in the peritoneal mucinous deposits, combined with normal tumour markers and normal imaging, make it difficult to outline the treatment that should be offered to our patient. If her diagnosis is PMP/DPAM, then she is at risk of recurrent PMP and should undergo cytoreduction and hyperthermic intraperitoneal chemotherapy, the currently accepted treatment. However, the similarity of her pathology to that of the three patients in the first of the above studies suggests that she could be treated conservatively, because up to the time of reporting PMP had not recurred in these patients.

The above considerations have led to a "wait and watch" approach to the management of our patient, with plans to carry out six monthly tumour marker measurements and annual computed tomography scans.

---

**Take home messages**

- We report a patient with a mature ovarian cystic teratoma in whom the appendix was normal and who presented with pseudomyxoma peritonei.
- The pathological, histological, and tumour marker characteristics of our patient make it difficult to classify this tumour into a distinct category (such as disseminated peritoneal adenomucinosis or peritoneal mucinous carcinomatosis) and advise the patient on the appropriate treatment.
- Therefore, we have decided to take a "wait and watch" approach, and plan to carry out six monthly tumour marker measurements and annual computed tomography scans.

---

**REFERENCES**


---

**Authors’ affiliations**

N Pranesh, M S Wilson, S T O’Dwyer, Department of Surgery, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK.

L P Menasce, Department of Pathology, Christie Hospital NHS Trust.

Full consent was given for the publication of this report.

Correspondence to: Mr N Pranesh, PMP Service, Surgical Theatres, Christie Hospital, Wilmslow Road, Withington, Manchester M20 4BX, UK; Nagarajan.Praneesh@christie-tr.nwest.nhs.uk

Accepted for publication 22 December 2004.


12 Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Tumori 2001;87:S3–5.